Chang Jin Wang
Founder bij FRONTIER BIOTECHNOLOGIES INC.
Vermogen: 20 M $ op 31-03-2024
Profiel
Chang Jin Wang is the founder of Frontier Biotechnologies, Inc. (China) since 2013, where he holds the title of General Manager & Director.
He previously held the position of Vice President-Business Development at VIVUS, Inc., Abmaxis, Inc., and TaiGen Biotechnology Co., Ltd.
from 2002 to 2006.
Dr. Wang holds a doctorate degree from the University of Kentucky and undergraduate and graduate degrees from West China University of Medical Sciences.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-09-2022 | 21 059 500 ( 12.47% ) | 20 M $ | 31-03-2024 |
Actieve functies van Chang Jin Wang
| Bedrijven | Functie | Begin |
|---|---|---|
| FRONTIER BIOTECHNOLOGIES INC. | Founder | 15-01-2013 |
Eerdere bekende functies van Chang Jin Wang
| Bedrijven | Functie | Einde |
|---|---|---|
Abmaxis, Inc.
 Abmaxis, Inc. Pharmaceuticals: MajorHealth Technology Abmaxis Inc. develops pharmaceutical drugs. The company discovers and optimizes monoclonal antibody (mAb) products for human therapeutics and diagnostics. It has developed antibody engineering technology platform, Abmaxis in-silico Immunization (AISIM TM), which they are used for building an internal product pipeline and collaboration with global biotech and pharmaceutical partners. The company was founded in 2000 and is located in Santa Clara, CA. | Corporate Officer/Principal | 01-07-2006 |
TaiGen Biotechnology Co., Ltd.
 TaiGen Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan. | Corporate Officer/Principal | 01-05-2004 |
| VIVUS, INC. | Corporate Officer/Principal | - |
Opleiding van Chang Jin Wang
| University of Kentucky | Doctorate Degree |
| West China University of Medical Sciences | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| FRONTIER BIOTECHNOLOGIES INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
VIVUS, Inc.
 VIVUS, Inc. Pharmaceuticals: MajorHealth Technology VIVUS, Inc. engaged in the development and commercialization of novel therapeutic products. The firm’s products were indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and it was headquartered in Campbell, CA. | Health Technology |
Abmaxis, Inc.
Abmaxis, Inc. Pharmaceuticals: MajorHealth Technology Abmaxis Inc. develops pharmaceutical drugs. The company discovers and optimizes monoclonal antibody (mAb) products for human therapeutics and diagnostics. It has developed antibody engineering technology platform, Abmaxis in-silico Immunization (AISIM TM), which they are used for building an internal product pipeline and collaboration with global biotech and pharmaceutical partners. The company was founded in 2000 and is located in Santa Clara, CA. | Health Technology |
TaiGen Biotechnology Co., Ltd.
TaiGen Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan. | Health Technology |
